RASTETTER WILLIAM H 4

What Happened
William H. Rastetter, a director of Neurocrine Biosciences, received an award of 2,567 restricted stock units (RSUs) on May 27, 2026. The Form 4 reports the acquisition as a derivative grant at an acquisition price of $0.00 (i.e., no cash was paid). Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026.
• Instrument: 2,567 RSUs (derivative); acquisition price reported $0.00.
• Vesting: RSUs vest in full on May 27, 2027 (see footnote).
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 — each RSU converts to one share upon vesting; F2 — full vesting on 5/27/2027.
• Timeliness: Filing occurred two days after the transaction date (filed within typical Form 4 reporting window).

Context
RSU grants are a form of compensation and do not involve an open‑market purchase or sale. They become actual shares only if and when they vest (here, one year after grant). Such awards are common for directors and executives and should be interpreted as compensation-related rather than a direct buy/sell signal.